Punit Parasher, MD
Cardiovascular Disease · Glendale, AZNPI 1316926579
Payments from drug & device makers
Across 347 payments — averaging $40.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$7K
- Novartis$1K
- Amgen$650
- Merck$517
- Boehringer Ingelheim$458
- Abbott$453
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$6,25044%
- Travel & lodging$7806%
- Food & beverage$7,14750%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 12 | $7,397 |
| Novartis | 97 | $1,409 |
| Amgen | 41 | $650 |
| Merck | 24 | $517 |
| Boehringer Ingelheim | 20 | $458 |
| Abbott | 6 | $453 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 29 | $419 |
| E.r. Squibb & Sons, L.L.C. | 23 | $352 |
| Medtronic | 2 | $305 |
| AstraZeneca | 9 | $249 |
| Bardy Diagnostics, Inc. | 8 | $205 |
| Kestra Medical Technology Services, Inc. | 8 | $205 |
| Impulse Dynamics (USA) Inc. | 6 | $203 |
| Johnson & Johnson | 10 | $179 |
| Actelion Pharmaceuticals US, Inc. | 7 | $157 |
| Lexicon Pharmaceuticals, Inc. | 3 | $156 |
| Pfizer | 9 | $155 |
| Cleerly, Inc. | 3 | $119 |
| Alnylam Pharmaceuticals Inc. | 7 | $118 |
| Baxter Healthcare | 3 | $77 |
| Sanofi-aventis U.S. LLC | 4 | $65 |
| Boston Scientific | 1 | $56 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $45 |
| Philips North America LLC | 1 | $39 |
| Bayer | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 2 | $33 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Recor Medical Inc | 1 | $22 |
| Astellas Pharma US Inc | 1 | $19 |
| Amarin Pharma, Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NORTHERA$7,291
- OPTIMIZER$295
- AZURE XT DR MRI SURESCAN$170
- CARDIOMEMS$155
- MitraClip$147
- COREVALVE EVOLUT R$135
- FARXIGA$135
- Inpefa$125
- LifeVest$113
- Corlanor$101
- Repatha$101
How this compares
$14,177 in reported general payments places this provider in the 75th percentile of 423 cardiovascular disease providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 505 | $610,530 |
| EntrestoSacubitril/Valsartan | 155 | $199,762 |
| XareltoRivaroxaban | 151 | $186,589 |
| FarxigaDapagliflozin Propanediol | 70 | $61,111 |
| Repatha SureclickEvolocumab | 62 | $60,947 |
| BrilintaTicagrelor | 20 | $16,815 |
| Metoprolol Succinate | 646 | $8,865 |
| Ranolazine ErRanolazine | 73 | $8,472 |
| Repatha SyringeEvolocumab | 14 | $7,760 |
| NexletolBempedoic Acid | 15 | $6,730 |
| Flecainide Acetate | 122 | $6,327 |
| Praluent PenAlirocumab | 12 | $5,976 |
| Valsartan | 176 | $4,862 |
| Atorvastatin Calcium | 420 | $4,459 |
| Nifedipine ErNifedipine | 147 | $4,142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $155 | $610,530505 claims |
| NovartisEntresto | $1,409 | $199,762155 claims |
| Johnson & JohnsonXarelto | $179 | $186,589151 claims |
| AstraZenecaFarxiga, Brilinta | $249 | $77,92690 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 423 cardiovascular disease providers in Arizona.
Other cardiovascular disease in Glendale
- Fred CucherGlendale$82K
- David RizikScottsdale$2.1M
- Rodrigo ChanMesa$2M
- Ashish GuptaPhoenix$1.2M
- Rajkumar SugumaranPhoenix$957K
- Krishnaswami VijayaraghavanScottsdale$927K
- Gregory KoshkarianTucson$608K
- Andrew KaplanMesa$455K
- Charles JostMesa$374K
- Steven MottlTucson$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.